This work is reported as an observational, prospective, multicenter study titled “Proteomic Immune Signatures of Severe HIV-Associated Tuberculosis in Sub-Saharan Africa: A Prospective, Multicenter Analysis From Uganda.” The article appears in Crit Care Explor (2026 Aug 27;8[9]:e1439) and is indexed on PubMed with PMID 42645154 and DOI 10.1097/CCE.0000000000001439. The PubMed record in the supplied source frames the manuscript as an eCollection and indicates the publication grouping and citation metadata.
The publication lists a large, multidisciplinary group of authors with affiliations spanning academic medical centers in the United States and clinical and research institutions in Uganda. Key institutional types represented include university divisions of pulmonary, critical care, allergy and immunology; departments of infectious diseases and epidemiology; the Uganda Virus Research Institute; regional Ministry of Health hospitals in Entebbe and Tororo; and the Rakai Health Sciences Program. Specific U.S.-based centers named in the source include the David Geffen School of Medicine at UCLA, Columbia University Vagelos College of Physicians and Surgeons, Icahn School of Medicine at Mount Sinai (Human Immune Monitoring Center), and the National Institute of Allergy and Infectious Diseases.
The PubMed entry classifies the report as an Observational Study and describes it as prospective and multicenter. The geographic focus is explicitly Sub-Saharan Africa, with data collection described as occurring in Uganda. The title indicates enrollment and analysis were conducted across multiple sites within Uganda, reflecting a multicenter design intended to capture clinical and immunologic data in that setting.
The central focus identified in the citation is the investigation of proteomic immune signatures associated with severe HIV-associated tuberculosis. The title positions proteomic profiling and immune signatures as the key scientific approach used to characterize severe disease among persons with HIV and tuberculosis in the study population in Uganda.
The supplied PubMed record provides the following bibliographic metadata:
The PubMed view available in the source includes extensive author and affiliation details but does not include the abstract or full-text content in the provided capture.
The version of the PubMed page supplied here includes detailed title, author and affiliation listings and bibliographic identifiers but does not include the abstract text, methods, results, statistical analyses, biomarker lists, numeric outcomes, figures, tables, or the authors’ conclusions. Because the source text provided is limited to the PubMed metadata and navigation elements, specific study details — including sample size, inclusion/exclusion criteria, proteomic platform(s) used, measured proteins or pathways, statistical modeling, and clinical implications — were not reported in the supplied source and therefore cannot be restated here.
When key manuscript sections are absent from the source, readers should consult the journal website, the full PubMed abstract (if available), or the article itself to obtain the complete methodological and result-oriented details required for clinical interpretation, validation of biomarkers, or application to practice.
From the bibliographic record alone, the study emphasizes an intersection of critical care–relevant infectious disease topics: severe tuberculosis occurring in persons living with HIV, evaluated using proteomic immune profiling in a Sub-Saharan African cohort. The multicenter, prospective design named in the title suggests primary data collection across Ugandan sites and an intent to generate clinically relevant immune signatures associated with severe disease. The multidisciplinary author list and involvement of specialized immune monitoring centers indicate collaboration between clinical sites and specialized proteomic/immunologic laboratories.
However, because the abstract and full text were not present in the supplied source, no information about the study’s findings, the proteins or immune pathways implicated, diagnostic or prognostic performance metrics, or suggested clinical applications can be reported here. Readers and clinicians who require the study’s empirical results, validated biomarker panels, or recommendations for patient care should access the full article through Crit Care Explor or PubMed to review methods, results, and authors’ interpretations.
Retrieve the full-text article via the DOI (10.1097/CCE.0000000000001439), the journal Crit Care Explor, or institutional access to review the abstract, methods, results, and conclusions.
Verify the study’s sample size, site list, proteomic platforms, and analytical methods to assess generalizability to local clinical populations.
If proteomic signatures or biomarker panels are reported, evaluate whether they were externally validated and whether they have defined thresholds, performance characteristics, or prospective utility for diagnosis, prognosis, or therapeutic guidance.
For implementation or research planning, confirm ethical approvals, specimen handling protocols, and data-sharing statements as provided in the full text.
Note: All statements above are limited to information available in the supplied PubMed source capture. Specific experimental results, statistical outcomes, and the authors’ interpretations were not included in the provided source and therefore are not reported here.